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Abstract There are several prognostic multigene-based
tests for managing breast cancer (BC), but limited data
comparing them in the same cohort. We compared the
prognostic performance of the EndoPredict (EP) test (s-
tandardized for pathology laboratory) with the research-
based PAM50 non-standardized qRT-PCR assay in node-
positive estrogen receptor-positive (ER?) and HER2-
negative (HER2-) BC patients receiving adjuvant
chemotherapy followed by endocrine therapy (ET) in the
GEICAM/9906 trial. EP and PAM50 risk of recurrence
(ROR) scores [based on subtype (ROR-S) and on subtype
and proliferation (ROR-P)] were compared in 536 ER?/
HER2- patients. Scores combined with clinical informa-
tion were evaluated: ROR-T (ROR-S, tumor size), ROR-
PT (ROR-P, tumor size), and EPclin (EP, tumor size, nodal
status). Patients were assigned to risk-categories according
to prespecified cutoffs. Distant metastasis-free survival
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(MFS) was analyzed by Kaplan–Meier. ROR-S, ROR-P,
and EP scores identified a low-risk group with a relative
better outcome (10-year MFS: ROR-S 87 %; ROR-P 89 %;
EP 93 %). There was no significant difference between
tests. Predictors including clinical information showed
superior prognostic performance compared to molecular
scores alone (10-year MFS, low-risk group: ROR-T 88 %;
ROR-PT 92 %; EPclin 100 %). The EPclin-based risk
stratification achieved a significantly improved prediction
of MFS compared to ROR-T, but not ROR-PT. All sig-
natures added prognostic information to common clinical
parameters. EPclin provided independent prognostic
information beyond ROR-T and ROR-PT. ROR and EP
can reliably predict risk of distant metastasis in node-pos-
itive ER?/HER2- BC patients treated with chemotherapy
and ET. Addition of clinical parameters into risk scores
improves their prognostic ability.
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Abbreviations
BC Breast cancer
ET Endocrine therapy
EP EndoPredict score
FEC 5-Fluorouracil, epirubicin, and
cyclophosphamide
FEC-P FEC followed by paclitaxel
FFPE Formalin-fixed paraffin embedded
MFS Metastasis-free survival
ROR Risk of recurrence
ROR-S ROR score based on subtype information
ROR-P ROR based on subtype and proliferation
ROR-T ROR based on subtype and tumor size
ROR-PT ROR based on subtype, proliferation, and
tumor size
vs Versus
Background
Gene expression tests are new tools to clinically determine
the risk of relapse in early-stage breast cancer (BC) [1, 2].
The 21-gene recurrence score (Oncotype DX) and Mam-
maprint (NKI-70) [3–10] have been shown to impact
treatment decisions [11–13]. Novel prognostic tests, such
as EndoPredict and PAM50, are also able to predict early,
as well as late metastases [14, 15].
EndoPredict is a standardized test for the molecular
pathology laboratory and was the first multigene test used
in a decentralized setting [16, 17]. It was established and
validated in two independent clinical validation studies
(ABCSG6 and ABCSG8) involving patients with ER?/
HER2- BC treated with adjuvant endocrine therapy (ET)
only [18]. EndoPredict provides prognostic information
beyond all common clinicopathological parameters [18]
and clinical guidelines [19]. The molecular information
(EP score) is further combined with tumor size and nodal
status resulting in the EPclin score.
The PAM50 assay is an optimized gene set used to
identify intrinsic subtypes and predict the Risk Of Recur-
rence (ROR) at 10 years [20, 21]. The ROR score was
developed in a microarray-based cohort of node-negative,
untreated BC patients [6, 20]. Four versions of ROR exist
in the research setting: ROR based on subtype information
(ROR-S), ROR-S with proliferation (ROR-P), ROR-S with
tumor size (ROR-T), and ROR-P with tumor size (ROR-
PT) [20, 21]. The minimum ROR score of all Luminal B
scores was assigned as the low-risk threshold for each
model and the maximum ROR score of all Luminal A
scores as the high-risk threshold [21].
The inclusion of established clinicopathological risk
factors in ROR and EP scores, such as tumor size (ROR-T,
ROR-PT, and EPclin) and nodal status (EPclin), increases
their predictive performance [18–21]. EndoPredict and
research-based PAM50 were evaluated independently in
the GEICAM/9906 trial [22–25]. We compared the prog-
nostic performance of the EP test with the research-based,
non-standardized PAM50 assay in node-positive, ER?/
HER2- BC patients treated with adjuvant chemotherapy
followed by ET.
Patients and methods
Patients and tumor samples
Patients in this study participated in the GEICAM/9906
trial, a randomized phase III trial that compared adjuvant
chemotherapy regimen of 5-fluorouracil, epirubicin, and
cyclophosphamide (FEC) with FEC followed by weekly
paclitaxel (FEC-P), and then followed by 5-year hormonal
therapy (tamoxifen, aromatase inhibitors or both) in 1246
women with lymph node-positive disease [26]. This trial
was performed in accordance with the Declaration of
Helsinki, approved by the ethics committees at all partic-
ipating institutions (see Supplementary Table 1S) and the
Spanish Health Authority, and registered at www.clin
icaltrials.gov (NCT00129922). Patients provided their
written informed consent for therapy randomization and
molecular analyses. Patients whose tumors were ER?/
HER2- according to a central review by qRT-PCR and
consented to genomic analysis were eligible.
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Formalin-fixed paraffin-embedded (FFPE) tumor blocks
used to compare PAM50 and EP scores were collected at
the time of surgery.
EndoPredict gene expression analysis
RNA extraction and gene expression analysis for identi-
fying the ER?/HER2- subgroup and performing the
EndoPredict have been recently described. Briefly, total
RNA was extracted from one 5-lm whole FFPE tissue
section using a silica bead-based, fully automated isolation
method (Tissue Preparation System, VERSANT Tissue
Preparation Reagents, Siemens Healthcare Diagnostics)
[27].
To identify patients with ER?/HER2- tumors, ESR1
and ERBB2 gene expression levels were analyzed and
predefined cut-off levels were applied as recently descri-
bed. The EP score is based on eight cancer-related genes
(BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP,
STC2) and three reference genes (CALM2, OAZ1,
RPL37A), and measured by qRT-PCR [18].
PAM50-ROR gene expression analysis
RNA was extracted from two 1-mm FFPE cores as previ-
ously described [20]. To determine the research-based
versions of the ROR scores and groups, normalized gene
expression data obtained from the qRT-PCR platform were
gene-median-centered, and the microarray-based PAM50
intrinsic subtype predictor was applied as previously
described [20]. Of note, the microarray-based training
dataset, from which survival coefficients were derived, is
based on patients with node-negative disease that did not
receive adjuvant systemic therapy [6]. In addition, ROR
thresholds (low and high) consist of subtype distributions
along the ROR scores in the training dataset [21].
Statistical analysis
The ROR and EP scores were calculated blinded to clinical
data and sent to the GEICAM study group in Madrid for
independent statistical analysis. Only the GEICAM group
had access to the combined clinical outcome and gene
expression data.
The primary endpoint was distant metastasis-free sur-
vival (MFS) estimated using the Kaplan–Meier method.
Pearson correlations compared gene signatures. Two-sided
log-rank tests were used to compare subgroups. P values
\5 % were considered statistically significant. Each gene
signature was added to a model containing common clin-
ical parameters and one other evaluated signature. C-indi-
ces were then calculated for the clinical variables and
model combinations to estimate the performance of each
variable for predicting distant metastasis. Differences were
evaluated using the log-likelihood ratio statistic test (for
proportional Cox model hazard rates) and the comparison
of c-index with resampling (both one-sided tests).
The PAM50 ROR-S, ROR-P, and ROR-T and ROR-PT
scores classified patients as low-, intermediate-, and high-
risk, using the following pre-defined cut-off values,
respectively: ROR-S (\24; 24–53; [53), ROR-P (\12;
12–53;[53), ROR-T (\29; 29–65;[65), PAM50 ROR-PT
(\18; 18–65; [65). Both, EP and EPclin categorized
patients into low- (EP score\5; EPclin score\3.3) and
high-risk groups (EP score C5; EPclin score C3.3) [18].
The following clinical parameters were used for the anal-
ysis: positive nodal status (1–3; 4–10;[10); tumor size [cm
(B1; [1–B2; [2–B5; [5)]; Grade (1; 2; 3); age; and
treatment arm (FEC; FEC-P).
Results
Patient population
A total of 566 (71 %) of 800 available tumor samples were
eligible for evaluation. Tumor samples lacking PAM50 or
EndoPredict data were excluded (5 %). Characteristics of
the patient cohort included in this study are summarized in
Supplementary Table 2S.
Risk categorization
Patients with ER?/HER2- BC were classified as low-risk
in 32, 20, and 25 % of cases based on the ROR-S, ROR-P,
and EP scores, respectively (Supplementary Table 3S). All
gene signatures identified low-risk groups with a significant
better outcome compared to the other risk groups (Fig. 1).
The 10-year MFS rates for low-risk groups were 87, 89,
and 93 %, respectively (Fig. 1). The EPclin low-risk group
was smaller (13 %) compared to ROR-T (22 %) and ROR-
PT (19 %) low-risk groups, but had a better, though not
statistically significant, 10-year MFS rate (100 vs. 88 vs.
92 %, Fig. 1).
Comparing EP versus PAM50 gene signatures
As continuous variables, EP was significantly correlated
with ROR-S (r = 0.72) and ROR-P (r = 0.68). Combining
the intermediate- and high-risk groups based on ROR-S
(ROR-T) and ROR-P (ROR-PT), resulted in a 21 and 20 %
discrepancy in patient categorization when comparing EP
vs. ROR-S and EP vs. ROR-P classifications, respectively.
The MFS of patients with discordant classification were
analyzed to compare EP vs. PAM50 risk assignments
yielding non-statistical significant differences. However,
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EP-based low-risk patients had a better outcome than
PAM50-based counterparts (Fig. 2). EPclin-based risk
classification proved a superior predictor of MFS than the
ROR-T score (P = 0.04), but not in comparison to the
ROR-PT (P = 0.09) (Fig. 2).
Prognostic performance of predictors
Compared to clinical parameters, ROR-S, ROR-P, and EP
molecular signatures had substantially higher c-indices
(Fig. 3) and added significant prognostic information
beyond clinical parameters based on c-index analysis and
resampling (data not shown). C-indices for EP, ROR-S,
and ROR-P were 0.657, 0.639, and 0.633, respectively.
C-indices for EPclin, ROR-T, and ROR-PT were 0.693,
0.649, and 0.644, respectively (Fig. 3).
Based on c-indices and resampling, we determined that
EP added prognostic information to ROR-P and clinical
parameters, but not to ROR-S. C-index was significantly
increased by adding EPclin to models containing clinico-
pathological parameters and ROR-T (P\ 0.001), or ROR-
bFig. 1 Kaplan–Meier curve for metastasis-free survival by EP, ROR-
S, ROR-P, EPclin, ROR-T, and ROR-PT risk groups. PAM50 ROR-S,
ROR-P, and ROR-T and ROR-PT scores stratify patients (GEICAM/
9906, N = 536) in low-risk, intermediate-risk and high-risk. EP and
EPclin stratify patients as low-risk for distant recurrence and high-risk
groups. Numbers in parentheses indicate the 95 % confidence interval
of the hazard ratio. EP EndoPredict score, EPclin EP based on tumor
size and nodal status, ROR risk of distant recurrence, ROR-S ROR
based on subtype, ROR-P ROR based on subtype and proliferation,
ROR-T ROR based on subtype and tumor size, ROR-PT ROR based
on subtype, proliferation, and tumor size
EP vs. ROR-S EP vs. ROR-P
EP-low, ROR-S inter/high 
(n = 37, 5 events)
EP-high, ROR-S –low
(n = 76, 16 events)
EP-low, ROR-P inter/high
(n = 68, 7 events)
EP-high, ROR-P –low
(n = 40, 8 events)
EPclin vs. ROR-T
EPclin-low, ROR-T inter/high
(n = 21, 0 events)
EPclin vs. ROR-PT
EPclin-low, ROR-PT inter/high 
(n = 24, 0 events)
EPclin-high, ROR-PT –low
(n = 54, 6 events)
EPclin-high, ROR-T –low
(n = 68, 12 events)
Fig. 2 Kaplan–Meier curves for metastasis-free survival by discor-
dant samples between EP and ROR scores. Kaplan–Meier curves by
EP–ROR-S, EP–ROR-P, EPclin–ROR-T, and EPclin–ROR-PT. Num-
bers in parentheses indicate the 95 % confidence interval of the
hazard ratio. EP EndoPredict score, EPclin EP based on tumor size
and nodal status, ROR risk of distant recurrence, ROR-S ROR based
on subtype, ROR-P ROR based on subtype and proliferation, ROR-T
ROR based on subtype and tumor size, ROR-PT ROR based on
subtype, proliferation, and tumor size
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PT (P\ 0.001). ROR-T and ROR-PT failed to add prog-
nostic information to EPclin (Table 1).
Discussion
We compared the prognostic performance of research-
based and non-standardized versions of PAM50-ROR
scores and EndoPredict in ER?/HER2-, node-positive
chemotherapy-treated BC patients from the GEICAM/9906
trial.
ROR-S and ROR-P were significantly correlated with
EP score, and gene signatures showed agreement in risk
classification, indicating that PAM50-ROR and EP scores
identify tumors with similar properties. Despite the sig-
nificant correlation, the discordance rate of 20–21 % can be
explained by the tests’ inherent characteristics. Our c-index
analysis indicated that only EP added significant informa-
tion to ROR-P. None of the other molecular signatures
added information to each other, suggesting that additional
predictors would not improve prognostic performance.
These findings are concordant with our previous combined
analysis of hundreds of signatures and clinical-pathological
data for prognostic prediction in ER-positive breast cancer
where we observed that not much more prognostic power
was obtained by including hundreds of signatures into a
single model beyond the power contained within a well-
developed individual signature when combined with clin-
ical variables [28].
The PAM50-based ROR-T and ROR-PT scores include
tumor size, whereas the EPclin score considers nodal status
and tumor size, as part of the risk prediction algorithm.
Similar to the research-based version, a ROR-PT score
weighted for tumor size and proliferation was used to
validate the standardized version of PAM50 assay in the
ATAC and ABCSG8 trials. In our analysis, all hybrid
scores contributed to identifying low-risk groups for distant
metastasis, although number of patients and events differed
across score categories. The EPclin low-risk group was
smaller than the ROR-T and ROR-PT ones and showed no
distant-metastatic events. EPclin had been established in a
node-positive/node-negative cohort and the predefined cut-
off level consequently classified more patients as high-risk
in the node-positive GEICAM/9906 trial. In contrast, the
research-based versions of ROR-T and ROR-PT scores
were derived in a systemically untreated node-negative BC
cohort, and thresholds were based on subtype distribution
and not actual survival outcomes; therefore, the number of
low-risk cases with distant-metastatic events was higher, as
reflected by an MFS of 87–92 % in low-risk groups.
Kaplan–Meier analysis of discordant cases, c-index
analysis, and log-likelihood tests showed that the EPclin-
based risk classification provided independent prognostic
information to the ROR-T and ROR-PT scores. The
improved performance of the EPclin score over pure
molecular scores may be partially explained by the
inclusion of nodal status, one of the strongest single
prognostic factors, in the EPclin score, but which is not
included in any of the other models tested. EndoPredict
validation studies demonstrated that molecular EP score,
tumor size, and nodal status were the only independent
prognostic parameters [18]. Hybrid scores’ superior per-
formance compared to their molecular counterparts sup-
ports the recommendation of the Evaluation of Genomic
Application in Practice and Prevention working group to
integrate clinicopathological factors into gene expression
tests [29] rather than relying on pure RNA-based molec-
ular scores.
To the best of our knowledge, our study reports the first
direct comparison of EndoPredict and a research-based
version of the PAM50 assay. Earlier comparisons of
multigene signatures suggested similar prognostic perfor-
mances [30, 31]. Recently, the transATAC study, the first
0.4 0.45 0.5 0.55 0.6 0.65 0.7
Age
Arm
Grade
Tumor Size
Nodal Status
ROR-S
ROR-P
EP
ROR-T
ROR-PT
EPclin
C-index
Fig. 3 Distribution of clinical and molecular parameters c-indices.
EP EndoPredict score, EPclin EP based on tumor size and nodal
status, ROR risk of distant recurrence, ROR-S ROR based on subtype,
ROR-P ROR based on subtype and proliferation, ROR-T ROR based
on subtype and tumor size, ROR-PT ROR based on subtype,
proliferation, and tumor size
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large phase III study comparing different standardized gene
expression-based biomarkers in the same patient cohort
[32], compared the standardized and clinically validated
version of PAM50 assay, developed under the nCounter
system (Nanostring Technologies), with the 21-gene
recurrence score. PAM50-ROR provided more prognostic
information than the recurrence score [32]. Although our
study did not evaluate the standardized and clinically val-
idated PAM50-ROR score, the GEICAM/9906 trial is an
additional valuable source for biomarker comparisons. In
the context of this trial, we could identify high-risk patients
who need additional treatment to the standard anthracy-
cline-based chemotherapy (±taxane) and could be eligible
for further treatment with novel drugs, such as CDK4/6 or
mTOR inhibitors.
Our results should be interpreted in the context of its
limitations. First, ROR scores were generated using
research-based and non-standardized versions from qRT-
PCR platform. Although research-based PAM50 classifi-
cation has been evaluated in several clinical trials using
qRT-PCR [22, 33, 34], different methods may influence
prognostic ability. Of note, large validation studies (ATAC
and ABCSG8) for the PAM50 assay were performed using
the standardized version with pre-specified cutoffs based
on actual survival outcomes (\10, 10–20, and[20 % risk
of distant relapse at 10 years) and not subtype distribution
[32]. Second, the PAM50 vs. EP comparison was not
conducted according to their intended use. Whereas our
patients were treated with chemotherapy, these predictors
were clinically validated using patients cohorts receiving
endocrine therapy alone. Therefore, next steps should
compare PAM50 and EP in clinical trials with ER?/
HER2- BC patients treated with ET alone. EndoPredict
and the standardized PAM50 were recently evaluated in the
ABCSG8 trial, which would allow a direct comparison of
both clinical predictors [35].
Conclusions
Despite the differences in establishment and the limited
overlap in genes, all molecular predictors evaluated
showed similar prognostic performance. The addition of
clinical parameters, such as tumor size and nodal status,
into risk-score determination improves the prognostic
ability of these assays.
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